Skip to main
VNRX
VNRX logo

Volitionrx Limited (VNRX) Stock Forecast & Price Target

Volitionrx Limited (VNRX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

VolitionRX Ltd has demonstrated a positive trend in its financial performance, with a reported revenue of $0.6 million, reflecting a 32% year-over-year increase, alongside a notable reduction in net loss by 8% and a 33% decrease in net cash used in operating activities, now at $3.6 million. The company is advancing its commercial efforts through strategic licensing agreements, including collaborations with Werfen and Hologic, which highlight its commitment to expanding its diagnostic offerings beyond research applications. Opportunities for growth are significant, particularly in oncology and geographic expansion, as well as leveraging prognostic biomarkers, which could drive improved clinical outcomes and increased market penetration in the evolving healthcare landscape.

Bears say

VolitionRX Ltd has experienced a decline in operating expenses, which decreased by 10% for the quarter and 18% year-to-date, suggesting a potential effort to manage costs amid challenging market conditions. Despite this reduction in expenses, the company continues to face significant hurdles in achieving revenue growth and market penetration in the highly competitive diagnostics space. The reliance on the Nucleosomics platform and its related products may limit the company's potential for expansion if clinical validation and widespread adoption do not materialize.

Volitionrx Limited (VNRX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Volitionrx Limited (VNRX) Forecast

Analysts have given Volitionrx Limited (VNRX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Volitionrx Limited (VNRX) has a Strong Buy consensus rating as of Dec 15, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $3.17, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $3.17, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Volitionrx Limited (VNRX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.